Formations et évènements
ASCO
29 Mai 2026 - 02 Juin 2026
Chicago
2 abstracts IFCT séléctionnés à l'ASCO 2026 :
IFCT-2401 SPORADIC trial: Integrating cemiplimab to sequential hypofractionated chemoradiotherapy for unfit or elderly patients with unresectable stage III non–small cell lung cancer.
S. Thureau - Poster session (Oral)
Paclitaxel, carboplatin, and durvalumab in extensive stage small-cell lung cancer (ES-SCLC; IFCT-2203 TAXIO phase II trial): Can we improve the chemotherapy (CT) immunotherapy combination in SCLC?
D. Moro-Sibilot - Poster session (Oral)